mTOR inhibitor-3 NEW
| Price | $55 | $129 | $189 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-07-16 |
Product Details
| Product Name: mTOR inhibitor-3 | CAS No.: 1207358-59-5 |
| Purity: 99% | Supply Ability: 10g |
| Release date: 2025/07/16 |
Product Introduction
Bioactivity
| Name | mTOR inhibitor-3 |
| Description | mTOR inhibitor-3 is a selective mTOR inhibitor (Ki= 1.5 nM). mTOR inhibitor-3 inhibits mTORC1 and mTORC2 in cellular and in vivo experiments. |
| In vitro | mTOR inhibitor-3 is an mTOR inhibitsor(Ki of 1.5 nM), 500-fold selectivity over closely related PI3 kinases. mTOR inhibitor-3 inhibits NCI-PC3 and MCF7neo/Her2 cells proliferation with IC50s of 150 nM and 57 nM, respectively[2]. |
| In vivo | mTOR inhibitor-3 achieves tumor stasis at the highest 200 mg/kg/day dose examined, which appears to also be approaching the limit of tolerability for this molecule. Plasma levels of mTOR inhibitor-3 6 h following oral administration in PC3 tumor-bearing mice along with the fold decreases of phosphorylated mTORC1 and -2 substrates relative to time-matched vehicle controls.mTOR inhibitor-3 has moderate terminal elimination half-life (t1/2=1.7 h for mouse(1 mg/kg, iv))[2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 40 mg/mL (84.29 mM), Sonication is recommended. |
| Keywords | mTOR inhibitor-3 | mTOR inhibitor3 | mTOR inhibitor 3 | mTOR | Mammalian target of Rapamycin | Inhibitor | inhibit |
| Inhibitors Related | α-Hydroxyglutaric Acid Lithium | L-Leucine | Capivasertib | Sapanisertib | Everolimus | Bimiralisib | Salidroside | GDC0084 | TMBIM6 antagonist-1 | P-2281 | Rapamycin | PI3K/Akt/mTOR-IN-2 |
| Related Compound Libraries | Bioactive Compound Library | HIF-1 Signaling Pathway Compound Library | Kinase Inhibitor Library | Anti-Breast Cancer Compound Library | Anti-Ovarian Cancer Compound Library | Antioxidant Compound Library | Inhibitor Library | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Liver Cancer Compound Library | Neuronal Differentiation Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $2500.00/100mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2025-04-29 | |
| $2800.00/100mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-10-28 | |
| $0.00/1g |
VIP5Y
|
WUHAN FORTUNA CHEMICAL CO., LTD
|
2021-06-22 | |
| $55.00/1mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2025-07-15 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY